BeiGene

What BeiGene does

BeOne Medicines I GmbH, operating as BeOne Medicines and formerly known as BeiGene, is a global oncology company founded in 2010 and headquartered in Basel, Switzerland (with major operations in Beijing and San Mateo). The company is dual-listed on NASDAQ (ticker ONC), HKEX, and the Shanghai Stock Exchange and markets three approved cancer medicines: BRUKINSA (zanubrutinib), the leading global BTK inhibitor approved in more than 80 markets and generating $3.9 billion in FY2025 sales at 49% year-over-year growth; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved in multiple solid tumor indications; and BEQALZI (sonrotoclax), the first and only FDA-approved BCL2 inhibitor for B-cell malignancies, approved in May 2026.

The company's pipeline spans hematology and solid tumors and includes BTK degraders (BGB-16673/tacabrutideg), a CDK4 inhibitor entering Phase 3 for first-line metastatic breast cancer, the anti-TIGIT antibody ociperlimab, the HPK1 inhibitor BGB-26808, the PRMT5 inhibitor BGB-58067, and the GPC3×4-1BB bispecific BGB-B2033. Underlying these programs are two proprietary technology platforms: CDAC (Conditionally Active Biodegradable Antibody Conjugates), a protein degradation modality, and an enhanced Antibody Drug Conjugate (ADC) platform. Clinical differentiation is anchored by long-duration efficacy data, including 71.8% progression-free survival at 78-month follow-up in CLL/SLL (SEQUOIA trial) and an 85.1% overall response rate for the BTK degrader in heavily pretreated relapsed/refractory CLL.

BeOne Medicines operates a hybrid commercial model: direct sales infrastructure across more than 80 markets including the US, EU, and China, supplemented by licensing partnerships such as the Glenmark deal for emerging markets and the Jazz Pharmaceuticals collaboration on zanidatamab (Ziihera). FY2025 product revenue reached $5.3 billion (40% year-over-year growth) at 88% gross margin, generating the company's first full-year GAAP net profit of $287 million and more than $940 million in free cash flow. Amgen holds an approximately 20.5% equity stake acquired in 2020.

Name

BeiGene

Legal name

BeOne Medicines I GmbH

Website

https://beigene.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Oncology pharmaceuticals
• Cancer immunotherapy
• BTK inhibitors
• PD-1 inhibitors
• Hematology treatments

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Revenue - BRUKINSA: BRUKINSA (zanubrutinib) is the company's flagship BTK inhibitor generating $3.9 billion in global sales in FY2025, representing 49% year-over-year growth. The drug is approved in 80 markets and maintains position as the leading BTK inhibitor globally. BRUKINSA generated $1.1 billion in Q4 2025 and is on track to generate approximately $5 billion in revenue in 2026.
2. Product Revenue - Tevimbra: Tevimbra (tislelizumab) is the company's PD-1 inhibitor generating $206 million in Q1 2026 revenue, 7% above analyst estimates. The drug is approved in multiple indications and received priority review from US FDA for first-line HER2+ gastroesophageal adenocarcinoma.
3. Product Revenue - BEQALZI (sonrotoclax): BEQALZI (sonrotoclax) received FDA approval in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies, representing a new revenue stream for the company. The drug has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
4. Partnership Revenue - Zanidatamab/Ziihera: BeOne Medicines partnered with Zymeworks on zanidatamab (Ziihera), which received FDA approval for biliary tract cancer and is being developed for HER2-positive gastroesophageal adenocarcinoma. The partnership includes milestone payments and royalty streams, with Jazz Pharmaceuticals collaborating on commercialization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.

Product overview

BeOne Medicines (BeiGene) is a global oncology company developing a broad portfolio of cancer medicines. The company's approved products include BRUKINSA (zanubrutinib), a leading BTK inhibitor approved in over 80 markets for B-cell malignancies; TEVIMBRA (tislelizumab), a PD-1 inhibitor for various solid tumors; and BEQALZI (sonrotoclax), a BCL2 inhibitor approved in May 2026. The pipeline includes investigational BTK degraders (BGB-16673, tacabrutideg), a PRMT5 inhibitor (BGB-58067), a bispecific antibody (BGB-B2033), a TIGIT inhibitor (ociperlimab), an HPK1 inhibitor (BGB-26808), and a CDK4 inhibitor in Phase 3 development. The company also develops proprietary technology platforms including CDAC (protein degradation) and ADC (antibody drug conjugates). Research focuses on hematology (blood cancers) and solid tumors (breast, gynecologic, gastrointestinal, lung, liver cancers).

Differentiator

Problem solved

Functional benefit

Products and services

• BRUKINSA (zanubrutinib) Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. BRUKINSA is the leading BTK inhibitor globally, approved in 80+ markets, and generated $3.9B in FY2025 sales with 49% YoY growth.
• TEVIMBRA (tislelizumab) Anti-PD-1 monoclonal antibody approved in multiple indications for the treatment of various solid tumors, including lung cancer and HER2-positive gastroesophageal adenocarcinoma. TEVIMBRA generated $206 million in Q1 2026 revenue and has received U.S. FDA Priority Review for first-line HER2+ GEA.
• BEQALZI (sonrotoclax) Next-generation BCL2 inhibitor approved by the U.S. FDA in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies. Demonstrated 100% ORR with 59.5% complete responses in treatment-naive CLL patients and has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
• Ziihera (zanidatamab) HER2-targeted bispecific antibody partnered with Zymeworks and co-commercialized with Jazz Pharmaceuticals for HER2-positive cancers. Approved for biliary tract cancer with positive Phase 3 data in gastroesophageal adenocarcinoma; eligible for up to $1.5 billion in potential milestone payments.

Quantifiable outcome

• 74% progression-free survival at 6 years in treatment-naïve CLL patients with BRUKINSA
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Blood Cancer UnitedcoreStrategic or Co-development Partner · 1 June 2026Expanded multi-year partnership announced June 2026 with BeOne committing US$5,000,000 over three years to support patient education, community engagement, and the blood cancer care continuum. Reinforces BeOne's hematology narrative and patient-centric approach.
• GlenmarkcoreChannel Partner/ Reseller/ DistributorGlenmark signed billion-dollar licensing deals with BeiGene to commercialize lung cancer and other oncology drugs across emerging markets. Treatments offered at ₹50,000 per session compared to ₹200,000-500,000 for Western alternatives, significantly expanding patient access.
• Ensem TherapeuticsminorStrategic or Co-development PartnerStrategic licensing collaboration for CDK2 inhibitor development targeting RAS-mutated tumors, part of BeOne's shift toward personalized and precision medicine approaches in prostate cancer and other solid tumors.
• ZymeworkscoreStrategic or Co-development PartnerPartnership on zanidatamab (Ziihera) for HER2-positive cancers. Positive Phase 3 data in gastroesophageal adenocarcinoma showed significant improvements in PFS and OS. Ziihera approved for biliary tract cancer with PDUFA date August 25, 2026 for GEA.
• Jazz PharmaceuticalscoreGTM or Marketing PartnerJazz Pharmaceuticals collaborating on commercialization of zanidatamab in HER2-positive gastroesophageal adenocarcinoma. Expects FDA approval and market launch in second half of 2026 with up to $1.5 billion in potential milestone payments from collaboration.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/beigeneusa
• LinkedInlinkedin.com/company/beigene

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BeiGene